Benzinga
Benzinga
Benzinga
samedi, septembre 26

Prime Medicine Inc

PRMENASDAQ
Trade with Public
Trade with Public
$2.90
-0.17-5.54%
À la clôture: Sep 25, 5:00 PM EST
$2.95
0.05381.86%
Après les heures: 7:58 PM EST
PRO
Pourquoi cela bouge-t-il ?:Prime Medicine shares are trading higher after the company announced the FD...
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatDividendesComparerOptionsRapport sur les stocks

Prime Medicine Analyst Price Targets

Wall Street analyst price targets and consensus rating for Prime Medicine (PRME).

Price Target Range — 12 Quarters

Analyst Consensus — 13 Analysts

2S.Buy
9Buy
2Hold
Consensus RatingOutperform# Analysts13Avg. Consensus PT$10Upside to Avg. PT+249.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →
DateFirmAnalystActionRating ChangePrice Target
Sep 25, 2026Chardan CapitalKeay NakaeMaintainedBuy$7
Aug 25, 2026Chardan CapitalKeay NakaeMaintainedBuy$7
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BMO Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $9

BMO Capital analyst David Lebowitz initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $9.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $8 Price Target

HC Wainwright & Co. analyst Arthur He reiterates Prime Medicine (NASDAQ:PRME) with a Buy and maintains $8 price target.
Benzinga Newsdesk

This Caseys Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday

Top Wall Street analysts upgraded Prime Medicine, Inc and Casey's General Stores Inc, and upgraded Warner Bros Discovery Inc with price targets.
Avi Kapoor

PRO
HC Wainwright & Co. Upgrades Prime Medicine to Buy, Announces $8 Price Target

HC Wainwright & Co. analyst Arthur He upgrades Prime Medicine (NASDAQ:PRME) from Neutral to Buy and announces $8 price target.
Benzinga Newsdesk

PRO
Oppenheimer Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $11

Oppenheimer analyst Kostas Biliouris initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $11.
Benzinga Newsdesk

PRO
LifeSci Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $6

LifeSci Capital initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $6.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved